Anti-Inflammatory Agents Flashcards
infliximab
DMARD
humanized Ab to TNF-alpha, binds it and prevents it from interacting with its receptor. Reduces circulating and local TNF-alpha, increased TNF alpha in joints and stool
Increases frequency of infections
Parenteral admin
adalimumab
DMARD
human Ab to TNF-alpha.
Increases frequency of infections
Parenteral admin
etancercept
DMARD
Fusion protein with ligand binding domain of TNF-alpha receptor: longer half life
Increases frequency of infections
Parenteral admin
etancercept
DMARD
Fusion protein with ligand binding domain of TNF-alpha receptor: longer half life
Increases frequency of infections
Parenteral admin
anakinra
DMARD
Competative IL1 Receptor Antagonist
Increases frequency of infections
Parenteral admin
tofacitinib
DMARD Jak kinase Inhibitor Oral inhibit cytokins Increases frequency of infections At high dose potent immunosuppression
diphenhydramine
H1 Receptor Antagonist
=Benadryl
1st generation: sedation and non-H1 effects - anticholinergic effects - dry mouth, urinary retention, tachycardia; serotonin block
diphenhydramine
H1 Receptor Antagonist
=Benadryl
1st generation: sedation and non-H1 effects - anticholinergic effects - dry mouth, urinary retention, tachycardia; serotonin block
dimenhydrinate
H1 Receptor Antagonist
=Dremamine
1st generation: sedation and non-H1 effects - anticholinergic effects - dry mouth, urinary retention, tachycardia; serotonin block
loratidine
H1 Receptor Antagonist
=Claritin
2nd generation - more selective for H1
cetrizine
H1 Receptor Antagonist
=Zyrtec
2nd generation - more selective for H1
fexofenadine
H1 Receptor Antagonist
=Allegra
2nd generation - more selective for H1
cromolyn
Release Inhibitor: Inhibits Ca2+ dependent degranulation of mast cells
nedocromil
Release Inhibitor: Inhibits Ca2+ dependent degranulation of mast cells
keterolac
NSAID - nonselective COX inhibitor
post surgical analgesic
